Drug intelligence / Profile preview

HXN6005

Development stage: Phase 2
Lead developer: Helixon
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

HXN6005 is a humanized monoclonal antibody developed by Helixon Biotechnology using its proprietary artificial intelligence-driven protein design platform. It is designed to target the alpha subunit of the interleukin-4 receptor (IL-4Rα). By binding to IL-4Rα, HXN6005 inhibits the signaling of both interleukin-4 (IL-4) and interleukin-13 (IL-13), which are key cytokines driving Type 2 (Th2) inflammation. This pathway is a well-validated target for the treatment of various allergic and inflammatory diseases, most notably asthma and atopic dermatitis. The drug is currently undergoing Phase I clinical trials to evaluate its safety, tolerability, and pharmacokinetic profile in healthy volunteers and individuals with asthma.

Targets

IL4R (Interleukin-4 receptor alpha subunit)

Beyond the preview

Go deeper on HXN6005.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HXN6005.

Explore the full profile